AI in Life Science Market Projected to Reach $69.34 Billion by 2031, Driven by Advanced AI Architectures: GlobeNewswire Report Overview

July 5, 2026

GlobeNewswire Global

Overview

This article provides an overview of a market research report distributed by GlobeNewswire. The AI in life science market is projected to reach USD 69.34 billion by 2031, growing at a CAGR of 26.3% from USD 21.58 billion in 2026. This growth is primarily driven by advanced AI architectures optimizing clinical trials, facilitating real-world evidence collection, and accelerating drug development. End-to-end solutions dominate the market, with North America leading due to robust research networks and digitalization investments.

In Depth

This article provides an overview of a market research report distributed by GlobeNewswire.

Report Overview

This market research report offers a detailed analysis of the current status and future projections for the AI in life science market. The report covers market trends across key segments including offering (solutions, services), application (drug discovery, clinical trials, R&D), tools (machine learning, natural language processing), and end-user (pharmaceutical and biotechnology companies, research organizations). It evaluates market size and growth opportunities in major regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study period for the forecast is from 2026 to 2031.

Key Findings

The AI in life science market is projected for substantial growth, expanding from USD 21.58 billion in 2026 to USD 69.34 billion by 2031, exhibiting a robust Compound Annual Growth Rate (CAGR) of 26.3% during the forecast period. This strong growth is primarily fueled by the increasing adoption of advanced AI architectures that are optimizing clinical trial design and execution, facilitating the collection of real-world evidence (RWE), and significantly accelerating the overall drug development lifecycle.

End-to-end solutions are dominating the market landscape, reflecting a broader industry shift towards integrated platforms for data ingestion, model building, validation, and deployment. Geographically, North America is anticipated to hold the largest market share, driven by its advanced research networks, proactive investments in healthcare digitalization, and the strong presence of major biotechnology and pharmaceutical companies.